logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2021
Aridis Pharmaceuticals Inc
Data from Phase IIa trial of AR-501
Cystic fibrosis
2H 2021
Summit Therapeutics plc
Top-line data from phase III trial of Ridinilazole (Ri-CoDIFy 1)
C. difficile infection
2H 2021
Summit Therapeutics plc
Top-line data from phase III trial of Ridinilazole (Ri-CoDIFy 2)
C. difficile infection
2H 2021
Aridis Pharmaceuticals Inc
Top-line data from phase III pivotal trial of AR-301
Acute pneumonia caused by S. aureus infection
2H 2021
PhaseBio Pharmaceuticals Inc
Results from Phase 2b clinical trial of PB1046
Pulmonary Arterial Hypertension
2H 2021
MIRAGEN THERAPEUTICS, INC.
Primary endpoint data from phase II trial of Cobomarsen ( SOLAR)
Mycosis fungoides (MF)
Q3 2021
Xenon Pharmaceuticals Inc.
Top-line results from phase IIb study of XEN1101 as adjunctive treatment
Focal epilepsy in adults
2H 2021
ERYTECH Pharma S.A
Final analysis from Phase 3 clinical trial evaluating the efficacy and safety of eryaspase(TRYbeCA-1)
Advanced metastatic pancreatic cancer
2H 2021
MacroGenics Inc.
Data from final overall survival analysis of the SOPHIA study of Margetuximab
HER2-positive metastatic breast cancer
2H 2021
Mereo BioPharma Group plc
Top-line data from phase II study of Alvelestat
Alpha-1 antitrypsin deficiency (AATD)
Q3 2021
Outlook Therapeutics, Inc.
Safety and efficacy data from phase III study of ONS-5010 (NORSE 2 )
wet age-related macular degeneration(wet AMD)
2H 2021
Kaleido Biosciences
Topline data from Phase 2 trial of KB195 (UNLOCKED)
Topline data from Phase 2 trial of KB195 (UNLOCKED)
2H 2021
Adverum Biotechnologies Inc.
Clinical data from phase 2 Clinical Trial of ADVM-022 (INFINITY)
Diabetic Macular Edema
2H 2021
Matinas BioPharma Holdings, Inc.
Topline data from phase 2 trial of MAT2203 ( EnACT)
Invasive fungal infections, including cryptococcal meningitis
2H 2021
Allakos Inc.
Topline data from phase 3 study of AK002
Eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD)
2H 2021
Allakos Inc.
Topline data from phase 2/3 study of AK002
Eosinophilic esophagitis (EoE)
2H 2021
Arcutis Biotherapeutics Inc.
Topline data from Phase 2b study of ARQ-151
Atopic dermatitis
Q3 2021
Atara Biotherapeutics, Inc.
Finalize Submission of BLA for tab-cel
EBV+ PTLD (Post transplant lymphoproliferative disease)
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of Imfinzi
Adjuvant bladder; liver (locoregional); biliary tract
cancer
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of Imfinzi + tremelimumab (POSEIDON)
First-line treatment of patients with Non-small cell lung cancer (NSCLC)
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of Lynparza (PROfound)
metastatic castration-resistant prostate cancer (mCRPC)
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of Enhertu (DESTINY-Breast01)
HER2-breast cancer
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of acalabrutinib vs. ibrutinib(ELEVATE-TN)
Patients with previously-treated high-risk chronic lymphocytic leukaemia (CLL)
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of (DELIVER)
Heart Failure with preserved ejection fraction(HFpEF)
2H 2021
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of PT027
Asthma